Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Sep 18, 2016 2:48pm
138 Views
Post# 25249907

Despite a composite moratality range of 27.5% to 55%...

Despite a composite moratality range of 27.5% to 55%...27.5% being predicted at trial start ( come on kids, we're talking shock, not sore throat 0

55% analyst report ( where did you get this number friend, NOT made public )

I suggest we follow the guidance of our CEO, and the 45% conveyed to us at Rodman and Renshaw just last week.

Let's pray that the 45% composite mortality is just on the last 176 patients.  In order to produce an overall composite mortality rate of 45% on 446 patients, the last 176 would have needed to produce a 66.5% or rounded 67% composite mortality.  In order to determine efficacy, we multiply by 2 for a number of 134.  We know the last 176 patients die at a rate of 62% (EAA > .6 & MODS > 9 ) when receiving SOC ( standard of care ).  To determine PMX efficacy we subtract 62 from 134 leaving 72.  Therefore if the 45% composite mortality is for ALL 446 patients, we have been killing 10% more in the PMX group over the last 30 months and 176 patients...OOOOppps that is NOT good and now it's received COMPASSIONATE CARE?  I think you've just answered your question Beecher and the 45% over the last 176 with a 62% SOC death rate suggests 34% ABSOLUTE EFFICACY again.  I ran this scenario awhile back and wondered how long it would take for the "card to be played"  Looks like this angle equals a 2,7 offsuit draw...fold'em chief

I remain the Squire


Bullboard Posts